Jonathan Chapman Appointed President and CEO of PTS Diagnostics

Jonathan Chapman brings 20 years of leadership experience in the medical device industry, most recently serving as President of ARKRAY USA, Inc.

Jonathan Chapman joins PTS Diagnostics with an accomplished track record regarding mergers and acquisitions, post-acquisition integration, global product launches, market identification, and strategic positioning.

I’m honored to join the PTS Diagnostics team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes and assessment of cardiovascular disease risk,” said Jonathan Chapman, President and CEO of PTS Diagnostics. “We will continue our legacy of bringing leading innovation to patients across the globe. PTS Diagnostics’ broad capabilities, world-class leadership team, and committed people give me great confidence about our future.”

Jonathan Chapman received a Bachelor of Arts from Sheffield University UK, LLM Commercial and Corporate Law from University of London (SOAS) and LLM Health Law from Hamline Law School, St. Paul, MN. PTS Diagnostics is confident that his international experience will be immensely valuable when leading the organization across global markets.

Mr. Chapman will be based out of the Whitestown, Ind. global headquarters.

As a comprehensive point-of-care diagnostics company, PTS Diagnostics manufactures solutions that close gaps in care for patients with chronic conditions such as diabetes, cardiovascular disease, and other related comorbidities.


Other executives in the news can be found here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version